Javier Cortés, MD, PhD

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Javier Cortés, MD, PhD, discusses primary outcomes and safety findings from a pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Javier Cortés, MD, PhD, discusses the incidence and management of male patients with breast cancer in Spain.

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.